Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. ROZLYTREK (entrectinib)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

ROZLYTREK (entrectinib)

Medicine - Posted on Aug 26 2021
Active substance (DCI)
  • entrectinib
history (2)
  • 7/21/21

    ROZLYTREK (entrectinib) (CPNPC)

    Key points Unfavourable opinion for reimbursement in the treatment of adult patients with ROS1-positive (ROS1+), advanced no...
    CAV :
    54321
    icône flèche
  • 7/21/21

    ROZLYTREK (entrectinib) (tumeurs solides)

    Key points Unfavourable opinion for reimbursement in adult and paediatric patients 12 years of age and older with solid tumo...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L01XE56
Manufacturer
ROCHE
Presentation

ROZLYTREK 100 mg, gélule
Boîte de 30 gélules - (Code CIP : 34009 302 129 9 8)

ROZLYTREK 200 mg, gélule
Boîte de 90 gélules - (Code CIP : 34009 302 130 1 8)

All our publications
    Cancers - miscellaneous Drug therapy Paediatrics Respiratory tract cancers

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
cbQJqkzGY30sZSH9